Form D · Biotechnology
MBio Diagnostics, Inc.
Boulder, CO · CIK 0001483426
Offering snapshot reported Mar 3, 2022 · SEC filing
- Reported sold
- $6.12M Offering amount: $9M
- Investors reported
- 12 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 18, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 3, 2022 | Initial | $6,120,000 | No comparison | 12 | SEC filing |
| Mar 22, 2021 | Initial | $1,725,000 | No comparison | 7 | SEC filing |
| Feb 2, 2021 | Initial | $9,990,000 | No comparison | 1 | SEC filing |
| Aug 3, 2020 | Amendment | $6,146,350 | $0vs Jul 31, 2020 | 16 | SEC filing |
| Jul 31, 2020 | Initial | $6,146,350 | No comparison | 11 | SEC filing |
| Mar 24, 2020 | Amendment | $1,585,000 | $1,035,000vs Feb 10, 2020 | 2 | SEC filing |
| Mar 24, 2020 | Amendment | $1,635,000 | $1,085,000vs Feb 10, 2020 | 2 | SEC filing |
| Feb 10, 2020 | Initial | $550,000 | No comparison | 2 | SEC filing |
| Aug 22, 2018 | Initial | $5,206,032 | No comparison | 10 | SEC filing |
| May 21, 2018 | Initial | $620,000 | No comparison | 5 | SEC filing |
| May 21, 2018 | Initial | $1,105,000 | No comparison | 1 | SEC filing |
| Aug 24, 2016 | Initial | $562,500 | No comparison | 3 | SEC filing |
| May 21, 2015 | Initial | $6,334,255 | No comparison | 14 | SEC filing |
| Sep 5, 2012 | Initial | $3,869,500 | No comparison | 9 | SEC filing |
| Jan 5, 2011 | Initial | $1,997,424 | No comparison | 19 | SEC filing |
Offering details
- Securities
- Debt, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-435698
The total offering amount includes convertible promissory notes convertible into shares of the company's capital stock.
Source: Form D, filed Mar 3, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Milton Chang | Director |
| Michael Chang | Director |
| Andrew Drenick | Director |
| Sarah C Hatcher | Executive |
| Michael J. Lochhaed | Executive |
| Michael J. Lochhead | Executive |
| Christopher Myatt | Director |
| Chris Myatt | Director, Executive |
| Judith O'brien | Director |
| Robert Silverman | Director |
| Nick Traggis | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
5603 Arapahoe Avenue Suite 1
Boulder, CO, 80303
Boulder, CO, 80303